Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Insilico Medicine (“Insilico”) announces that the team, with the support of its generative chemistry engine, has developed a ...

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

AARON Chalmers’ ex Talia Oatway has shared the emotional moment their son Oakley walked for the first time after his ...

Scientific Advisory Board formed with internationally recognized liver and biliary tract cancer physicians to support the advancement of solid tumor pipeline programs; Elevar plan ...

Sanjiv Patel, President and CEO of Relay Therapeutics, Inc. (NASDAQ:RLAY), a $656 million market cap biotech company currently trading at $3.96, recently executed notable stock transactions as ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

Real-world survival differences in advanced biliary tract cancer patients with ctDNA detected IDH1 mutations and FGFR2 fusions receiving first-line gemcitabine-cisplatin with and without immunotherapy ...